| Online-Ressource |
Verfasst von: | Hummel, Margit [VerfasserIn]  |
| Buchheidt, Dieter [VerfasserIn]  |
| Reiter, Sebastian [VerfasserIn]  |
| Bergmann, Jörg [VerfasserIn]  |
| Adam, Katja [VerfasserIn]  |
| Hehlmann, Rüdiger [VerfasserIn]  |
Titel: | Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase |
Verf.angabe: | Margit Hummel, Dieter Buchheidt, Sebastian Reiter, Jörg Bergmann, Katja Adam, Rüdiger Hehlmann |
E-Jahr: | 2005 |
Jahr: | 10 November 2005 |
Umfang: | 4 S. |
Fussnoten: | Gesehen am 11.05.2022 |
Titel Quelle: | Enthalten in: European journal of haematology |
Ort Quelle: | Oxford : Wiley-Blackwell, 1987 |
Jahr Quelle: | 2005 |
Band/Heft Quelle: | 75(2005), 6, Seite 518-521 |
ISSN Quelle: | 1600-0609 |
Abstract: | Abstract: Introduction: Rasburicase is a recombinant urate oxidase that is produced by a genetically modified Saccharomyces cerevisiae and has been approved for prophylaxis and treatment of tumor lysis syndrome in 2001. In several studies, rasburicase, given at a dose of 0.15-0.2 mg/kg for up to 7 d, proved to be highly effective in lowering urate levels. Case report: We report the case of a patient with chronic lymphatic leukemia (CLL) who experienced tumor lysis syndrome (TLS) with acute renal failure after fludarabine/cyclophosphamide chemotherapy and after bendamustine treatment. During the first episode of TLS, after fludarabine/cyclophosphamide (creatinine 3.3 mg/dL, urate 24.6 mg/dL), the patient received rasburicase 0.2 mg/kg for 3 d. Urate levels decreased below the lower limit of normal and renal function recovered. After bendamustine therapy, given for disease progression 8 months later, TLS with acute oliguric renal failure re-occurred (creatinine 3.1 mg/dL, urate 20.8 mg/dL). The patient was treated with hyperhydration and two doses of rasburicase (0.056 mg/kg), resulting in a prompt decrease of the urate level and recovery of renal function. Both episodes of TLS were successfully treated with rasburicase in a lower dose than recommended by the manufacturer. During a second bendamustine course, TLS was successfully treated by low doses of rasburicase (0.056 mg/kg for 2 d). Conclusion: This is the first report of TLS in CLL after bendamustine chemotherapy reported in the literature. Treatment and prevention of TLS by low doses of rasburicase is possible and cost-effective. |
DOI: | doi:10.1111/j.1600-0609.2005.00550.x |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1111/j.1600-0609.2005.00550.x |
| Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0609.2005.00550.x |
| DOI: https://doi.org/10.1111/j.1600-0609.2005.00550.x |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | chronic lymphocytic leukemia |
| hyperuricemia |
| rasburicase |
| renal failure |
| tumor lysis syndrome |
| urate oxidase |
K10plus-PPN: | 1801387516 |
Verknüpfungen: | → Zeitschrift |
Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase / Hummel, Margit [VerfasserIn]; 10 November 2005 (Online-Ressource)